What is the purpose of FMC's $114 million Delaware property sale, and how will operations be affected?

FMC signed a framework agreement to sell its Newark, Delaware, property for approximately $114 million to reduce debt while maintaining research and development capabilities at the site through a leaseback arrangement; the transaction is designed to convert underutilized real estate into capital without disrupting operations at its Stine Research Center—the company's global R&D headquarters—and is expected to close in the fourth quarter of 2026.

What uncertainties surround the Delaware property deal, and what does FMC say about its final outcome?

The framework agreement allows for renegotiation of key terms—including the leaseback arrangement and operational and economic details—during the due diligence period, and FMC explicitly stated: 'As a result, there can be no assurance that the framework agreement will ultimately result in any transaction.'

FMC reaches deal to sell Delaware property for $114M

Jun 24, 2026

FMC Corp agreed to sell its Newark, Delaware property for $114 million to reduce debt, maintaining R&D operations through a leaseback arrangement. This transaction supports the company's strategic review and debt-reduction goals alongside recent asset sales and technology deals.

chemweek

2026-04-30

FMC Beats Estimates, But Q2 Guidance Falls Short of Consensus

2026-06-24

FMC reaches deal to sell Delaware property for $114M

2026-07-07

Tessenderlo to Acquire 20% Stake in FMC

2026-09-26

Tessenderlo Closes $403 Million Investment in FMC

FMC reaches deal to sell Delaware property for $114M

FAQ